5 research outputs found
Troglitazone suppresses telomerase activity independently of PPARγ in estrogen-receptor negative breast cancer cells
<p>Abstract</p> <p>Background</p> <p>Breast cancer is one the highest causes of female cancer death worldwide. Many standard chemotherapeutic agents currently used to treat breast cancer are relatively non-specific and act on all rapidly dividing cells. In recent years, more specific targeted therapies have been introduced. It is known that telomerase is active in over 90% of breast cancer tumors but inactive in adjacent normal tissues. The prevalence of active telomerase in breast cancer patients makes telomerase an attractive therapeutic target. Recent evidence suggests that telomerase activity can be suppressed by peroxisome proliferator activated receptor gamma (PPARγ). However, its effect on telomerase regulation in breast cancer has not been investigated.</p> <p>Methods</p> <p>In this study, we investigated the effect of the PPARγ ligand, troglitazone, on telomerase activity in the MDA-MB-231 breast cancer cell line. Real time RT-PCR and telomerase activity assays were used to evaluate the effect of troglitazone. MDA-MB-231 cells had PPARγ expression silenced using shRNA interference.</p> <p>Results</p> <p>We demonstrated that troglitazone reduced the mRNA expression of hTERT and telomerase activity in the MDA-MB-231 breast cancer cell line. Troglitazone reduced telomerase activity even in the absence of PPARγ. In agreement with this result, we found no correlation between PPARγ and hTERT mRNA transcript levels in breast cancer patients. Statistical significance was determined using Pearson correlation and the paired Student's <it>t </it>test.</p> <p>Conclusions</p> <p>To our knowledge, this is the first time that the effect of troglitazone on telomerase activity in breast cancer cells has been investigated. Our data suggest that troglitazone may be used as an anti-telomerase agent; however, the mechanism underlying this inhibitory effect remains to be determined.</p
Characterization and Cloning of the mRNAs Specific for the Lactating Mouse Mammary Gland
The Marine-Derived Filamentous Fungi in Biotechnology
For a long time considered as essentially terrestrial organisms, filamentous fungi have recently disclosed to be widespread in marine habitats. Such a pervasiveness not only concerns obligate marine species but also a multitude of taxa known from disparate terrestrial substrates whose occurrence at sea, at first considered incidental, is now regarded as an evidence of extreme ecological flexibility. Actually, the peculiar physico-chemical properties of the marine environment are presumed to have induced special physiological adaptations that could be considered in view of a possible biotechnological exploitation of fungal strains recovered from marine sources. The potential of filamentous fungi reported from marine contexts for the manifold applications in biotechnology involving microbial strains is revised in this chapter